Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine is under clinical development by Sinovac Biotech and currently in Phase III for Seasonal Influenza. According to GlobalData, Phase III drugs for Seasonal Influenza have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine overview
Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) Vaccine (QIV) is an egg-based, quadrivalent vaccine. QIV contains, A/Guangdong-Maonan/SWL1536/2019 (H1N1), A/Hong Kong/2671/2019 (H3N2), B/Washington/02/2019 (Victoria line), and B/Phuket/3073/2013 (Yamagata strains). It is formulated as injectable solution for intramuscular route of administration. It is indicated for active immunization against influenza influenza A subtype viruses and type B viruses contained in the vaccine in adults and children over 3 years old.
It is under development for the treatment of seasonal influenza.
Sinovac Biotech overview
Sinovac Biotech is a biopharmaceutical company that develops, manufactures and commercializes vaccines. The company’s products comprise healive, an inactivated hepatitis A vaccine; bilive, a combined inactivated hepatitis A and B vaccine; anflu, a split viron influenza vaccine; panflu, a vaccine against the H5N1 influenza and inlive, an enterovirus type 71 vaccine. Sinovac Biotech also developed panflu.1, a vaccine against the influenza A H1N1 virus. The company conducts research to develop novel vaccines for infectious diseases including SARS, avian influenza, H1N1 influenza and hand foot and mouth disease. The company markets its products across China and abroad. Sinovac Biotech is headquartered in Beijing, China.
For a complete picture of Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
